Eli Lilly and Almirall’s Ebglyss (lebrikizumab) has been shown to significantly improve the signs and symptoms of atopic ...

The International Medical Derm Summit 2025 highlighted China's dermatological advancements, fostering global collaboration ...

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

A recent study found that teens who view cannabis and e-cigarette posts on social media are at risk. The Keck School of ...

Galderma begins 2 new clinical trials to investigate efficacy and safety of nemolizumab to treat patients with systemic sclerosis: Zug, Switzerland Friday, June 27, 2025, 13:00 Hr ...

Air pollution and temperature extremes were linked to increased atopic dermatitis visits, in a meta-analysis.

Eczema Types: Atopic Dermatitis Diagnosis and Treatment -- A Guide for Patients – An American Academy of Dermatology Association Reading Room selection June 19, 2025 • 9 min read ...

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.

The disease burden of atopic dermatitis was high in pediatric patients, but factors affecting the burden differed between adolescents and children.

The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.

Atopic dermatitis manifests differently on dark versus light skin, making equitable treatment challenging.